Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 08 Mar 2023
A new study from Edith Cowan University (ECU) has shown that understanding the following motivations can help find personal goals and prevent dementia.
Read Full NewsClinicians continue prescribing antibiotics unnecessarily despite growing evidence supporting shorter, targeted, and reassessed treatment strategies.
Nearly 300 experts warn that rising vaccine misinformation is reversing gains — measles and meningococcal infections are resurging while France updates the 2026 schedule.
Patients were randomly assigned 1:1 to receive either concurrent radiation dose escalation to the lumpectomy cavity during whole-breast irradiation or sequential boost after whole-breast irradiation.
The agency OK’d trastuzumab deruxtecan for two indications in HER2-positive early-stage breast cancer, covering both the neoadjuvant and adjuvant settings.
1.
GLP-1 drugs linked to dramatically lower death rates in colon cancer patients
2.
Preoperative MRI is useful for identifying additional disease in breast cancer patients with nodes positive.
3.
PFS in Multiple Myeloma Is Improved by Daratumumab Added to Standard Therapy.
4.
TULSA Is Effective in Long-Term Prostate Cancer Control.
5.
Rising rates of head and neck cancers in England
1.
Case Study: Advancing Preclinical Oncology Drug Development with Quantitative Systems Pharmacology
2.
Anion Gap: The Simple Calculation That Reveals Much About Your Health
3.
Understanding Mantle Cell Lymphoma Prognosis.
4.
Bridging Heart and Cancer Care: The Essential Framework of a Modern Cardio-Oncology Program
5.
Liquid Biopsy: Revolutionizing Precision Oncology in Hematological Malignancies
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Efficient Management of First line ALK-rearranged NSCLC
2.
The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management- Further Discussion
3.
Efficient Management of First line ALK-rearranged NSCLC - Part III
4.
Dacomitinib Case Presentation: Baseline Treatment and Current Status
5.
An In-Depth Look At The Signs And Symptoms Of Lymphoma
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge